HUP0400988A2 - Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására - Google Patents

Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására

Info

Publication number
HUP0400988A2
HUP0400988A2 HU0400988A HUP0400988A HUP0400988A2 HU P0400988 A2 HUP0400988 A2 HU P0400988A2 HU 0400988 A HU0400988 A HU 0400988A HU P0400988 A HUP0400988 A HU P0400988A HU P0400988 A2 HUP0400988 A2 HU P0400988A2
Authority
HU
Hungary
Prior art keywords
compounds
nep
medicaments
preparation
inhibitory activity
Prior art date
Application number
HU0400988A
Other languages
English (en)
Inventor
Claudia Berger
Yvan Fischer
Dagmar Höltje
Harald Waldeck
Michael Weske
Dieter Ziegler
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of HUP0400988A2 publication Critical patent/HUP0400988A2/hu
Publication of HUP0400988A3 publication Critical patent/HUP0400988A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya (a) semleges endopeptidázzal (NEP) és (b) IGS5metalloproteázzal - azaz a szekvencialistában 2-es, 4-es és 6-ossorszámmal jelölt aminosav-szekvenciák egyikével legalább 70 %-banmegegyező aminosav-szekvenciát tartalmazó polipeptiddel szembenkombinált - elsősorban konkurens - gátló hatást kifejtő vegyületek,valamint gyógyászatilag alkalmazható sóik, szolvátjaik és biológiailaglabilis észtereik felhasználása NEP és IGS5 kombinált - elsősorbankonkurens - gátlása útján visszaszorítható vagy megelőzhetőbetegségben vagy állapotban szenvedő vagy ilyen betegségre vagyállapotra hajlamos emlősök (előnyösen emberek) kezelésére alkalmasgyógyszerkészítmények gyártásához. Ó
HU0400988A 2001-05-18 2002-05-14 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments HUP0400988A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112231 2001-05-18
US29233701P 2001-05-22 2001-05-22
PCT/EP2002/005259 WO2002094176A2 (en) 2001-05-18 2002-05-14 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments

Publications (2)

Publication Number Publication Date
HUP0400988A2 true HUP0400988A2 (hu) 2004-08-30
HUP0400988A3 HUP0400988A3 (en) 2006-07-28

Family

ID=32842671

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400988A HUP0400988A3 (en) 2001-05-18 2002-05-14 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments

Country Status (15)

Country Link
US (1) US20040162345A1 (hu)
EP (1) EP1397141A2 (hu)
JP (1) JP2004536063A (hu)
CN (1) CN1520299A (hu)
AR (1) AR039352A1 (hu)
BR (1) BR0209855A (hu)
CA (1) CA2447598A1 (hu)
CZ (1) CZ20033183A3 (hu)
HU (1) HUP0400988A3 (hu)
MX (1) MXPA03010341A (hu)
PL (1) PL367093A1 (hu)
RU (1) RU2003136077A (hu)
SK (1) SK14102003A3 (hu)
WO (1) WO2002094176A2 (hu)
ZA (1) ZA200308098B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149416A0 (en) 1999-11-19 2002-11-10 Solvay Pharm Bv Human enzymes of the metalloprotease family
CA2493808A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
CN101076339B (zh) * 2004-01-12 2011-02-09 索尔瓦药物有限公司 用于预防和治疗神经变性疾病的中性内肽酶(NEP)和人可溶内肽酶(hSEP)抑制剂
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
WO2005112939A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
AU2005256634B2 (en) * 2004-06-23 2010-12-09 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists
EP1827448A1 (en) * 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
CA2596922A1 (en) * 2005-02-18 2006-08-24 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
KR101970505B1 (ko) * 2012-12-26 2019-04-19 (주)아모레퍼시픽 멜라닌 형성 억제제를 함유하는 미백용 피부 외용제 조성물
IL253661B2 (en) 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a pentagonal ring, pharmaceutical preparations and their uses
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
UY37845A (es) * 2017-08-15 2020-06-30 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
SG11202001166RA (en) 2017-08-15 2020-03-30 Inflazome Ltd Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MA50567A (fr) 2017-11-09 2020-09-16 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20020086405A1 (en) * 2000-09-25 2002-07-04 Inmaculada Silos-Santiago 56638, a novel human neprilysin protease and uses thereof
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
JP2001275687A (ja) * 2000-04-04 2001-10-09 Masafumi Matsuo 膜結合型メタロプロテアーゼ及びその可溶性分泌型
US6991916B2 (en) * 2000-07-14 2006-01-31 Pfizer Inc. Compounds for the treatment of sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20030119714A1 (en) * 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
ZA200308098B (en) 2004-10-18
CA2447598A1 (en) 2002-11-28
CZ20033183A3 (cs) 2004-07-14
RU2003136077A (ru) 2005-08-10
US20040162345A1 (en) 2004-08-19
MXPA03010341A (es) 2004-03-10
BR0209855A (pt) 2004-06-15
PL367093A1 (en) 2005-02-21
AR039352A1 (es) 2005-02-16
EP1397141A2 (en) 2004-03-17
SK14102003A3 (sk) 2004-08-03
WO2002094176A3 (en) 2003-12-11
HUP0400988A3 (en) 2006-07-28
CN1520299A (zh) 2004-08-11
WO2002094176A2 (en) 2002-11-28
JP2004536063A (ja) 2004-12-02

Similar Documents

Publication Publication Date Title
HUP0400988A2 (hu) Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására
HUP0100815A2 (hu) Neurológiai és neuropszichiátriai rendellenességek kezelésére szolgáló gyógyszerkészítmények
HUP0102365A2 (hu) Lipofil glükokortikoszteroidot és csak egy felületaktív anyagot tartalmazó micellákból álló gyógyszerkészítmények, valamint eljárás előállításukra
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
HUP9902698A2 (hu) Humán bikunin
ES2150447T3 (es) Formas purificadas de desoxiribonucleasa.
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
TR200101120T2 (tr) Serin proteaz inhibitörü
ATE162075T1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
SE9804614D0 (sv) New peptides and use thereof
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
HUP0500039A2 (hu) Vakcina és eljárás mozgatóneuron-betegségek kezelésére
HUP0400386A2 (hu) Cetirizint és pszeudoefedrint tartalmazó tabletta és alkalmazása gyógyszerkészítmények előállítására
NO996468D0 (no) Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees